Tumor necrosis factor α induces three-dimensional cytomorphologic differentiation of human anaplastic thyroid carcinoma cells through activation of nuclear factor κB

Cancer

Volumn 95, Issue 9, 2002, Pages 1827-1833

  Wang, Chih Yuan ^a,b   Zhong, Wen Bin ^b   Chang, Tien Chun ^a   Lai, Shu Mei ^b   Tsai, Yuan Feen ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Differentiation; Nuclear factor B; Three dimensional cytomorphology; Thyroid anaplastic carcinoma; Tumor necrosis factor

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE; RETINOIC ACID; SOMATOSTATIN; THYROGLOBULIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANAPLASTIC CARCINOMA; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROVILLUS; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN SECRETION; THREE DIMENSIONAL IMAGING; THYROID CARCINOMA; THYROID CELL;

CARCINOMA; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICROSCOPY, ELECTRON; MICROSCOPY, ELECTRON, SCANNING; MICROVILLI; NF-KAPPA B; PEPTIDES; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036840369     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10857     Document Type: Article

References (36)

1. Goretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg. 1993;80:1009-1012.
2. Nesland JM, Sobrinho-Simões M, Johnnessen JV. Scanning electron microscopy of the human thyroid gland and its disorders. Scanning Microsc. 1987;1:1797-810.
3. Sobrinho-Simões M, Johnnessen JV. A scanning and transmission electron microscopic study of human nodular goiter. Histopathology. 1983;7:65-76.
4. Weryha G, Marchal L, Leclere J, Grignon G, Hartemann P. Scanning electron microscopy (SEM) of the human thyroid gland: A technical improvement for follicular cell observation. J Submicrosc Cytol Pathol. 1990;22:459-464.
5. Chang TC, Lai SM, Wen CY, Hsiao YL, Huang SH. Three-dimensional cytomorphology and its relationship with clinical stage in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol. 2000;44:633-639.
6. Johnnessen JV, Sobrinho-Simões M. Follicular carcinoma of the human thyroid gland: An ultrastructural study with emphasis on scanning electron microscopy. Diag Histopathol. 1982;5:113-127.
7. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
8. Beutler B. TNF, immunity and inflammatory disease: Lessons of the past decade. J Invest Med. 1996;43:227-235.
9. Baldwin AS Jr. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol. 1996;14:649-681.
10. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today. 1998;19:80-88.
11. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243-252.
12. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
13. Baichwal VR, Baeuerle PA. Activate NF-kappa B or die? Curr Biol. 1997;7:R94-R96.
14. Lipton SA. Janus faces of NF-kappa B: Neurodestruction versus neuroprotection. Nat Med. 1997;3:20-22.
15. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med. 1998;188:2175-2180.
16. Ammon C, Mondal K, Andreesen R, Krause SW. Differential expression of the transcription factor NF-kappaB during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochem Biophys Res Commun. 2000;268:99-105.
17. Haley KJ, Patidar K, Zhang F, Emanuel RL, Sunday ME. Tumor necrosis factor induces neuroendocrine differentiation in small cell lung cancer cell lines. Am J Physiol. 1998;275:L311-L321.
18. Feng Z, Porter AG. NF-κB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J Biol Chem. 1999;274:30341-30344.
19. Siebenlist U. NF kappa B/I kappa B proteins. Their role in cell growth, differentiation and development. Biochem Biophys Acta. 1997;1332:R7-R13.
20. Harada T, Kunihiko I, Shimako F. Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma. Cancer. 1977;39:2588-2596.
21. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998;22:569-574.
22. Hoelting T, Duh QY, Clark OH, Herfarth C. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab. 1996;81:2638-2641.
23. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membranepermeable motif and nuclear localization sequence. J Biol Chem. 1995;70:14255-14258.
24. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in Stage I non-small lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8:72-79.
25. Loncaster JA, Cooper RA, Logue JP, Davison SE, Hunter RD, West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000;83:620-625.
26. Katoh R, Miyagi E, Kawaoi A, et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol. 1999;30:891-897.
27. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748-753.
28. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997;82:3741-3747.
29. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid. 2000;10:393-406.
30. Simon D, Koehrle J, Reiner C, et al. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998;22:569-574.
31. Kontgen F, Grumont R, Strasser A, Metcalf RL, Tarlinton D, Gerondakis S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995;9:1965-1977.
32. Doi TS, Takahashi T, Taguchi O, Azuma T, Obata Y. NF-kappa B RelA-deficient lymphocytes: Normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med. 1997;185:953-961.
33. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-κB controls cell growth and differentiation through regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
34. Bergé-Lefranc JL, Cartouzou G, De Micco C, Fragu P, Lissitzky S. Quantification of thyroglobulin messenger RNA by in situ hybridization in differentiated cancers. Difference between well-differentiated and moderately differentiated histologic types. Cancer. 1985;56:345-350.
35. Ohta K, Endo T, Onaya T. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues. Biochem Biophys Res Commun. 1991;174:1148-1153.
36. Shi Y, Zou M, Farid NR. Expression of thyrotropin receptor gene in thyroid carcinoma is associated with a good prognosis. Clin Endocrinol (Oxford). 1993;39:264-268.